Skip to main content
大唐药业 logo

大唐药业 — Investor Relations & Filings

Ticker · 920433 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2023-04-25 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920433

About 大唐药业

http://www.nmdt.com.cn/

Inner Mongolia Datang Pharmaceutical specializes in the research, development, and production of traditional Chinese and Mongolian medicines. The company focuses on modernizing ethnic medicinal formulas through advanced biotechnology and standardized manufacturing processes. Its product portfolio covers therapeutic areas including respiratory health, cardiovascular conditions, and gastrointestinal disorders. Notable offerings include Xuanfei Zhike granules and specialized Mongolian medicinal preparations. The organization integrates traditional knowledge with contemporary clinical research to develop proprietary formulations. By maintaining rigorous quality management systems and investing in automated production lines, the company aims to enhance the efficacy and accessibility of ethnic medicines for a broad patient base.

Recent filings

Filing Released Lang Actions
中泰证券股份有限公司关于内蒙古大唐药业股份有限公司2022年度募集资金存放及使用情况的专项核查报告
Regulatory Filings
2023-04-25 Chinese
第三届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 11th meeting of the 3rd Board of Directors of Inner Mongolia Datang Pharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to various reports and announcements published elsewhere. The document primarily concerns board meeting decisions and management reports rather than the reports themselves. It does not contain full financial statements or detailed financial data but rather summaries and approvals of reports and plans. The content fits the category of Board/Management Information (MANG), as it announces changes, approvals, and reports related to the company's board and senior management activities.
2023-04-25 Chinese
2023年一季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as the "2023 First Quarter Report" of Inner Mongolia Datang Pharmaceutical Co., Ltd., indicating it is a quarterly financial report. It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, and cash flow statements for the period ending March 31, 2023. The report includes management assurances about the accuracy and completeness of the quarterly report, and explicitly states it is unaudited. The content is comprehensive and substantive, covering financial data and analysis for a period shorter than a full fiscal year (the first quarter). This matches the definition of an Interim / Quarterly Report (IR). The document length is about 15,000 characters, which is consistent with a full report rather than a brief announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2023
2023-04-25 Chinese
会计政策变更公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding changes in accounting policies by the company, detailing the nature of the changes, the dates they take effect, and the approvals by the board, supervisory committee, and independent directors. It does not contain financial statements or detailed financial data but rather explains the policy changes and their compliance with regulations. The document length is short (1635 characters) and it is a formal announcement of accounting policy changes, not a full financial report or audit report. This fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2023-04-25 Chinese
独立董事关于第三届董事会第十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various proposals discussed at the company's board meeting, including profit distribution, use of raised funds, stock repurchase, senior management remuneration, appointment of auditors, related party transactions, and accounting policy changes. It is a formal announcement related to board meeting resolutions and opinions, not a full financial report or audit report. The content aligns with Board/Management Information (MANG) as it concerns board meeting decisions and management-related matters. The document length is short and focused on board opinions rather than detailed financial data or full reports.
2023-04-25 Chinese
拟续聘会计师事务所公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the company's intention to reappoint an accounting firm (audit firm) for the 2023 fiscal year. It details the qualifications, integrity records, and independence of the proposed audit firm, as well as the board and audit committee's approval process. There is no actual audit report or financial statements included, nor is there detailed financial data or analysis. The document is relatively short (3000 characters) and serves as a formal announcement of the audit firm appointment process rather than the audit report itself. Therefore, it is best classified as an Audit Report / Information (AR) type, which covers standalone audit-related announcements and information about audit firms, excluding full annual reports. FY 2023
2023-04-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.